And whether you know...
Korvitin, sodium hydroxide.
The lyophilized powder (porous dry hygroscopic weight with a slight specific smell of yellow color) in a bottle of 0,5 g, in packaging cardboard No. 5.
Pharmacodynamics and pharmacokinetics
Meletin is included into subgroup of flavanols, has the antioxidant effect caused by its ability to suppress process of peroxide oxidation of lipids. Meletin reduces concentration of toxic products of a peroksidation and free radicals, stimulates isoforms of a superoxide scavenger (SOD) katalazny activity.
Antiinflammatory and antiallergic effect of drug are caused by Korvitin's ability to suppress activity of a gilauronidaza, synthesis of leukotrienes and kaltsy-Atfazu. The antineoplastic effect is based on ability of drug to inhibit process of phosphorylation of proteins, and also on antioxidant and antiproliferative action. Suppresses trombogenez, possesses positive inotropic action on muscles of ventricles of heart (a papillary muscle).
The antiarrhytmic effect is caused by suppression of an oxidative stress and oppression of leukotrienes. Cardiotyre-tread action is caused by stimulation of process of production of nitrogen oxide that promotes improvement of a metabolism in an ishemirovanny site. Drug improves processes of recovery of microcirculation and blood circulation after a heart attack and a stroke, recovers a tone of vessels without the expressed changes. Meletin promotes growth of population of cells of immune system (lymphocytes, phagocytosis) that reduces manifestations of secondary immunodeficience.
Drug after parenteral administration is quickly absorbed in an organism. In blood the maximum concentration is reached in one minute. Meletin forms permanent communication with proteins of plasma. Gets through GEB. It is metabolized through gepatobiliarny system, removed by kidneys.
Indications to use
- In complex treatment of a myocardial infarction at acute insufficiency of coronary circulation; at HSN in the period of a decompensation;
- In complex treatment of disturbances of blood circulation head brain, caused by acute ischemia (a stroke ischemic, tranzitorny ischemic attacks) and brain diseases which cornerstone chronic ischemic processes are.
High sensitivity to drug and to HP with R-vitamin activity, children's age, at the expressed arterial hypotension, during pregnancy and a lactation.
In cases of fast administration of drug, and also at its use in a combination with organic nitrates there is a risk of development of moderately expressed arterial hypotension. In single cases the headache, a tremor, the general weakness, dizziness, a sonitus, excitement, pain behind a breast, a fever, local allergic reactions, the complicated breath are possible. hyperemia of the person.
Korvitin, application instruction (Way and dosage)
Drug Korvitin gets divorced isotonic NaCl solution (0,9%). It is necessary to enter 50 ml of solution and to stir up a bottle before full dissolution of powder.
At an acute myocardial infarction Korvitin is entered intravenously in the first days in a dosage of 0,5 g of drug, at once directly after hospitalization, further, in 2 hours and the subsequent dose — in 12 hours. To enter slowly, within 15 – 20 minutes. During the second and third day the drug is administered in a dosage 0,5 g twice a day with an interval of 12 hours. For the fourth and fifth days — once a day in a dose of 0,25 g.
At an acute stroke Korvitin is entered in a dosage of 0,5 g intravenously after hospitalization in 2 and 12 hours. During the second and third day the drug is administered in a dosage 0,5 g twice a day in 12 hours. Throughout the fourth — the tenth days once a day in a dose of 0,5 g.
Clinically expressed symptoms at overdose of drug are absent.
Not to dissolve drug in solution of a dextrose and reopoliglyukin. At Korvitin's reception together with nitrates hypotensive effect of nitrates amplifies. Korvitin at joint reception from fibrinolitika increases risk of development of thrombolytic complications. Korvitin is pharmacological not compatible to other solutions and drugs. Drug can be combined with protivotrombotichesky, antiarrhythmic, anti-anginal and fibrinolitic HP.
Terms of sale
According to the recipe.
At a temperature no more than 25 °C. Ready solution to store at 2-8 °C no more than 12 hours.
Period of validity
Coincidence on the ATH code of the 4th level:
According to responses of doctors, Korvitin's inclusion in the scheme of treatment of a myocardial infarction at patients with symptoms of acute heart failure contributes to normalization of pumping function of heart and reduces dilatation of a cavity of a left ventricle. Especially expressed effect is noted in the first days of an acute myocardial infarction at patients with dysfunction of a muscle of a left ventricle. Use of drug in the early period of a disease promotes a degrowth of a nekrotizirovanny myocardium.
Drug is effective also an intensive care of patients with an acute ischemic stroke. Its appointment allows to reach fuller and rather fast functional recovery of such patients, and also increases to 78% an indicator of an absolute recovery of patients to the end of the acute period of a stroke. Administration of drug promotes reduction of subjective symptomatology, and also improvement emotional a condition of patients.
PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Korvitin surely consult with the attending physician.